apocell Home Contact Us
  • CLINICAL TRIAL EXPERIENCE
    120
    SPECIMENS ANALYZED
    64,018
  • proposal request contact us

  • News

    February 4, 2010

    ApoCell Awarded Contract to Develop Circulating Tumor Cell Isolation Technology (ApoStreamTM) from NCI's Division of Cancer Treatment and Diagnosis (DCTD)

    June 1, 2011, Houston

    ApoCell Launches Revolutionary Circulating Cancer Cell Detection System - ApoStreamTM

    August 10, 2011, Houston

    ApoCell Awarded $2.9M from SAIC-Frederick, Inc. to Deliver a New Platform for Detection and Molecular Analysis of Circulating Tumor Cells

    August 24, 2011, Houston

    ApoCell named to Inc Magazine's List of the 5000 Fastest Growing Private Companies

    September 23, 2011, Houston

    ApoCell named to Houston Business Journal's List of the 100 Fastest-Growing Private Companies in Houston

    September 30, 2011, Houston

    ApoCell awarded SBIR Grant to Develop Point of Care Device for Antibody Independent Isolation of Circulating Tumor Cells

    November 11, 2011, Houston

    ApoCell Publishes Data Demonstrating the Improved CTC Capture Capabilities of the ApoStreamTM Device

    April 1, 2012, Houston

    ApoCell's CTC Capture Technology First To Reliably Detect and Recover Deadly Liver Cancer Cells

  • Conferences

  • Publications

    antiangiogenic cancer therapy
Home : About ApoCell : Publications : Journal Articles

Illuminating biomarker detection – Leading the way in personalized medicine.

2012

  • de Souza JA, Davis DW, Zhang Y, Khattri A, Seiwert TY, Aktolga S, Wong SJ, Kozloff MF, Nattam S, Lingen MW, Kunnavakkam R, Stenson K, Blair EA, Bozeman J, Dancey JE, Vokes EE, Cohen EEW. “A Phase II Study of Lapatinib in Recurring/Metastatic Squamous Cell Carcinoma of the Head and Neck” Clin Cancer Res OnlineFirst February 27, 2012; DOI: 10.1158/1078-0432.

    • 2009

  • Cohen E, Davis DW, Karrison T, Seiwert T, Wong S, Nattam S, Kozloff M, Clark J, Yan D, Liu W, Pierce C, Dancey J, Stenson K, Blair E, Dekker A, Vokes E.
    “Erlotinib and bevacizumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck: a phase I/II study”
    Lancet. 2009 February 9, 2009 DOI:10.1016/S1470-2045(09)70002-6

    • 2005

  • Berger AJ, Davis DW, Tellez C, Prieto VG, Gershenwald JE, Johnson MM, Rimm DL, Bar-Eli M.
    “Automated quantitative analysis of activator protein-2alpha subcellular expression in melanoma tissue microarrays correlates with survival prediction.”
    Cancer Res. 2005 Dec 1;65(23):11185-92.
  • Davis DW, Takamori R, Raut CP, Xiong HQ, Herbst RS, Stadler WM, Heymach JV, Demetri GD, Rashid A, Shen Y, Wen S, Abbruzzese JL, McConkey DJ.
    “Pharmacodynamic analysis of target inhibition and endothelial cell death in tumors treated with the vascular endothelial growth factor receptor antagonists SU5416 or SU6668.”
    Clin Cancer Res. 2005 Jan 15;11(2 Pt 1):678-89.

    • 2004

  • Heymach JV, Desai J, Manola J, Davis DW, McConkey DJ, Harmon D, Ryan DP, Goss G, Quigley T, Van den Abbeele AD, Silverman SG, Connors S, Folkman J, Fletcher CD, Demetri GD.
    ” Phase II study of the antiangiogenic agent SU5416 in patients with advanced soft tissue sarcomas.”
    Clin Cancer Res. 2004 Sep 1;10(17):5732-40.
  • Davis DW, Inoue K, Dinney CP, Hicklin DJ, Abbruzzese JL, McConkey DJ.
    ” Regional effects of an antivascular endothelial growth factor receptor monoclonal antibody on receptor phosphorylation and apoptosis in human 253J B-V bladder cancer xenografts.”
    Cancer Res. 2004 Jul 1;64(13):4601-10.
  • Davis, D.W., Shen, Y., Mullani, N.A., Wen, S., Herbst, R.S., OReilly, M.S., Abbruzzese, J.L., McConkey, D.J.
    “Quantitative analysis of biomarkers defines an optimal biological dose for recombinant human endostatin in primary human tumors.”
    Clin Cancer Res. 2004 Jan 1;10(1 Pt 1):33-42.

    • 2003

  • Davis, D.W., McConkey, D.J., Abbruzzese, J.L., Herbst, R.S.
    “Surrogate markers in antiangiogenesis clinical trials.”
    Br J Cancer. 2003 Jul 7;89(1):8-14. Review.
  • Davis, D.W., McConkey, D.J., Wei Zhang, Herbst, R.S.
    “Antiangiogenic Tumor Therapy.”
    Antiangiogenic tumor therapy. Biotechniques. 2003 May;34(5):1048-50, 1052, 1054 passim. Review.
  • Davis DW, Buchholz TA, Hess KR, Sahin AA, Valero V, McConkey DJ.
    “Automated quantification of apoptosis after neoadjuvant chemotherapy for breast cancer: early assessment predicts clinical response.”
    Clin Cancer Res. 2003 Mar;9(3):955-60.

    • 2002

  • Herbst R.S., Mullani N.A., Davis D.W., Hess K.R., McConkey D.J., Charnsangavej C., OReilly M.S., Kim H.W., Baker, C., Roach, J., Ellis L.M., Rashid, A., Pluda J., Bucana, C., Madden, T.L., Tran, H.T., Abbruzzese J.L.
    ” Development of Biologic Markers of Response and Assessment of Antiangiogenic Activity in a Clinical Trial of Human Recombinant Endostatin.”
    J Clin Oncol. 2002 Sep 15;20(18):3804-14.
  • McConkey, D.J., Davis, D.W.
    “Apoptosis and taxol therapy.”
    Cancer Biol Ther. 2002 Mar-Apr;1(2):118-20.

    • 2001

  • Liu, W., Davis, D.W., Ramirez, K., McConkey, D.J., and Ellis, L.M.
    “Endothelial Cell Apoptosis is Inhibited by a Soluble Factor Secreted by Human Colon Cancer Cells.”
    Int. J. Cancer, 92:26-30, 2001.

    • 1999

  • Shaheen, R. M., Davis, D. W., Liu, W., Zebrowski, B. K., Wilson, M. R., Bucana, C. D., McConkey, D. J., McMahon, G., and Ellis, L. M.
    “Antiangiogenic therapy targeting the tyrosine kinase receptor for vascular endothelial growth factor receptor inhibits the growth of colon cancer liver metastasis and induces tumor and endothelial cell apoptosis.”
    Cancer Res., 59: 5412-5416, 1999.
    		•
    home | contact
    Copyright © 2009-2011 ApoCell. All rights reserved.